Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis.
Jacky Chi-Yan LeeKoon-Ho ChanPublished in: Pharmaceutics (2024)
Multiple sclerosis is an important neurological disease affecting millions of young patients globally. It is encouraging that more than ten disease-modifying drugs became available for use in the past two decades. These disease-modifying therapies (DMTs) have different levels of efficacy, routes of administration, adverse effect profiles and concerns for pregnancy. Much knowledge and caution are needed for their appropriate use in MS patients who are heterogeneous in clinical features and severity, lesion load on magnetic resonance imaging and response to DMT. We aim for an updated review of the concept of personalization in the use of DMT for relapsing MS patients. Shared decision making with consideration for the preference and expectation of patients who understand the potential efficacy/benefits and risks of DMT is advocated.
Keyphrases
- multiple sclerosis
- end stage renal disease
- magnetic resonance imaging
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- mass spectrometry
- systemic lupus erythematosus
- rheumatoid arthritis
- pregnant women
- preterm birth
- disease activity
- contrast enhanced
- subarachnoid hemorrhage